WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 正面盈利預告 本公告乃由本公司根據上海證券交易所股票上市規則的規定及香港聯合交易 所有限公司證券上市規則第13.09(2)(a)條及香港法例第571章《證券及期貨條例》 第XIVA部有關披露義務的規定，在上海證券交易所及香港聯合交易所有限 公司同步刊登。董事會謹此公告，預期本公司於截至2025年12月31日止年度 營業收入及歸屬於本公司股東的淨利潤相比2024年年度同期將錄得上升。 股東及有意投資者在買賣本公司證券時務須謹慎行事。 本公告乃由無錫藥明康德新藥開發股份有限公司（「本公司」或「公司」）根據上 海證券交易所股票上市規則的規定及香港聯合交易所有限公司證券上市規則 第13.09(2)(a)條及香港法例第571章《證券及期貨條例》第XIVA部有關披露義務 ...

Core Viewpoint - WuXi AppTec (603259.SH) expects a net profit of 19.151 billion yuan for the year 2025, representing a year-on-year increase of approximately 103% [1] Financial Performance - The expected basic earnings per share for the period is approximately 6.70 yuan per share, reflecting a year-on-year growth of about 104.27% [1] - The increase in net profit includes gains from the sale of partial equity in an associate company and the divestiture of certain business segments [1] Business Strategy - The company continues to focus on its unique "integrated, end-to-end" CRDMO (Contract Research, Development, and Manufacturing Organization) business model [1] - WuXi AppTec is committed to meeting customer demands for empowerment, continuously expanding new capabilities, building new production capacity, and optimizing production processes to enhance operational efficiency [1] Non-Recurring Gains - The impact of non-recurring gains on the net profit attributable to shareholders mainly comes from the net gain of approximately 4.161 billion yuan from the sale of part of its stake in WuXi XDCCayman Inc. [1] - Additionally, the net gain from the sale of 100% equity in Shanghai Kangde Hongyi Medical Research Co., Ltd. and Shanghai WuXi Jinshi Pharmaceutical Technology Co., Ltd. is expected to be around 1.434 billion yuan [1]

Core Viewpoint - WuXi AppTec expects to achieve approximately RMB 45.456 billion in revenue for the fiscal year 2025, representing a year-on-year growth of about 15.84% [1] - The adjusted net profit attributable to shareholders is projected to be around RMB 14.957 billion, reflecting a year-on-year increase of approximately 41.33% [1] - The net profit attributable to shareholders is estimated to reach approximately RMB 19.151 billion, showing a significant year-on-year growth of about 102.65% [1] Revenue and Profit Growth - The anticipated revenue growth is primarily driven by the company's focus on its unique "integrated, end-to-end" CRDMO business model [1] - The increase in net profit is also attributed to gains from the sale of partial equity in joint ventures and the divestiture of certain business segments [1]

Core Viewpoint - WuXi AppTec expects to achieve a revenue of approximately RMB 45.456 billion in 2025, representing a year-on-year growth of about 15.84% [1] - The adjusted net profit attributable to shareholders is projected to be around RMB 14.957 billion, reflecting a year-on-year increase of approximately 41.33% [1] - The net profit attributable to shareholders is anticipated to reach approximately RMB 19.151 billion, showing a significant year-on-year growth of about 102.65% [1] Revenue and Profit Growth - The expected revenue growth is driven by the company's focus on its unique "integrated, end-to-end" CRDMO business model [1] - The increase in net profit is also attributed to gains from the sale of partial equity in joint ventures and the divestiture of certain business segments [1]

Core Viewpoint - WuXi AppTec (603259.SH) expects significant revenue and profit growth for the fiscal year 2025, driven by its integrated CRDMO business model and increasing client demand for enabling services [1] Financial Performance - The company anticipates a revenue of approximately RMB 45.456 billion, representing a year-on-year increase of about 15.84% [1] - Adjusted net profit attributable to shareholders is expected to be around RMB 14.957 billion, reflecting a year-on-year growth of approximately 41.33% [1] - The net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be about RMB 13.241 billion, with a year-on-year increase of approximately 32.56%, primarily impacted by exchange rate fluctuations [1] - Total net profit is expected to reach approximately RMB 19.151 billion, marking a year-on-year growth of about 102.65% [1] - The total profit for the period is projected to be around RMB 23.906 billion, indicating a year-on-year increase of approximately 107.16% [1] - Basic earnings per share are expected to be around RMB 6.70, reflecting a year-on-year growth of approximately 104.27% [1] Business Strategy - The company continues to focus on its unique "integrated, end-to-end" CRDMO business model, aiming to meet the growing client demand for enabling services [1] - WuXi AppTec is committed to expanding new capabilities, building new production capacity, and continuously optimizing production processes to enhance operational efficiency [1] - The company aims to drive steady business growth while efficiently empowering clients and striving to deliver more new and effective drugs to global patients [1]

药明康德公告称，预计2025年实现营业收入约454.56亿元，同比增长15.84%，其中持续经营业务收入同 比增21.40%；经调整归母净利润约149.57亿元，同比增长41.33%；扣非净利润约132.41亿元，同比增长 32.56%；归母净利润约191.51亿元，同比增长102.65%；基本每股收益约6.70元/股，同比增长 104.27%。业绩增长因公司聚焦CRDMO业务模式，且非经常性损益包括出售股权等净收益约55.95亿 元。 ...

Core Insights - The Huabao CSI Hong Kong Stock Connect Medical Theme ETF (159137) closed with a gain of 0.38% on January 12, with a trading volume of 173 million yuan [1] Fund Overview - The fund was established on December 31, 2025, and is officially named Huabao CSI Hong Kong Stock Connect Medical Theme Exchange-Traded Fund [1] - The management fee is set at 0.50% per annum, while the custody fee is 0.10% per annum [1] - The performance benchmark for the fund is the return of the CSI Hong Kong Stock Connect Medical Theme Index, adjusted for the RMB exchange rate [1] Fund Management - The current fund manager is Zhang Fang, who has managed the fund since its inception, achieving a return of 4.33% during the management period [1] Top Holdings - The latest report indicates that the top holdings of the ETF include: - WuXi Biologics: 2.65% holding, valued at approximately 7.49 million yuan [2] - JD Health: 2.02% holding, valued at approximately 5.71 million yuan [2] - WuXi AppTec: 1.44% holding, valued at approximately 4.07 million yuan [2] - Crystal Digital Holdings: 0.98% holding, valued at approximately 2.76 million yuan [2] - Alibaba Health: 0.93% holding, valued at approximately 2.63 million yuan [2] - WuXi AppTec Holdings: 0.86% holding, valued at approximately 2.43 million yuan [2] - Sinopharm: 0.72% holding, valued at approximately 2.04 million yuan [2] - Genscript Biotech: 0.55% holding, valued at approximately 1.55 million yuan [2] - Ping An Good Doctor: 0.46% holding, valued at approximately 1.31 million yuan [2] - CSPC Pharmaceutical Group: 0.41% holding, valued at approximately 1.17 million yuan [2]

Group 1 - Insilico Medicine announced a collaboration with Servier valued at $888 million focused on the discovery and development of innovative anti-cancer therapies [1] - Insilico will receive up to $32 million in upfront and milestone payments, leveraging its AI-driven drug development platform [1] - Servier will lead the clinical validation and commercialization of promising drug candidates globally [1] Group 2 - Weigao Blood Products announced a major asset restructuring involving the acquisition of 100% equity in Weigao Purui for approximately $8.511 billion [2] - Post-transaction, Weigao Purui will become a wholly-owned subsidiary, expanding the company's business into pharmaceutical packaging [2] - Weigao's shareholding in Weigao Blood Products will increase to 84.36%, maintaining absolute control [2] Group 3 - Earendil Labs (HuaShen ZhiYao) entered a strategic partnership with Sanofi worth up to $2.56 billion for the development of bispecific candidates targeting autoimmune and inflammatory diseases [3] - Earendil Labs will receive up to $160 million in upfront and milestone payments linked to early project outcomes [3] - The agreement includes tiered royalties based on net sales [3] Group 4 - WuXi AppTec announced that its controlling shareholders have reduced their stake by 2%, totaling 59.68 million shares [4] - The reduction was completed as per the previously disclosed plan, with the controlling shareholders holding 18.211% of the total shares before the reduction [4] Group 5 - Nanhua Biological announced plans for a significant asset restructuring to acquire 51% of Huize Pharmaceutical for cash [5] - The transaction is expected to constitute a major asset restructuring without involving share issuance or control changes [5] - Due diligence and negotiations are ongoing, with no formal agreement signed yet [5] Group 6 - Kangchen Pharmaceutical projected a net profit of between 145 million to 175 million yuan for 2025, representing a year-on-year increase of 243% to 315% [6] - The expected net profit excluding non-recurring gains is projected to be between 140 million to 170 million yuan, reflecting a significant increase from the previous year [6] Group 7 - Yilian Biotech signed a new exclusive licensing agreement with Roche for the YL201 project, with an upfront payment of $570 million [7] - The agreement allows Roche exclusive rights to develop and commercialize the YL201 project globally, excluding mainland China and certain regions [7] - This partnership builds on a successful collaboration on the YL211 project, aiming to accelerate the development of YL201 [7]

Group 1 - The Hong Kong Stock Exchange (HKEX) will launch six new stock options on January 19, 2026, expanding the stock options market and providing investors with more choices [2] - The new stock options will include Zijin Mining International (02259), WuXi AppTec (02359), BeiGene (06160), Lao Poo Gold (06181), Horizon Robotics (09660), and CanSino Biologics (09926) [2] - The average daily trading volume of the derivatives market at HKEX reached a record high of 1,662,751 contracts last year, representing a 7% year-on-year increase [2] Group 2 - Stock options, including monthly and weekly expiry contracts, were among the most actively traded products, with an average daily trading volume of 879,831 contracts, marking a 22% year-on-year increase [2] - The new stock options will have varying contract sizes, such as 200 shares for Zijin Mining International and BeiGene, and 500 shares for WuXi AppTec [3] - The launch will include contracts for multiple months in 2026, specifically January, February, March, April, June, September, and December for certain stocks [3]

Core Viewpoint - Hong Kong Stock Exchange (HKEX) will launch six new stock options on January 19, 2026, expanding the stock options market and providing investors with more choices [1] Group 1: New Stock Options - The new stock options will include Zijin Gold International (02259), WuXi AppTec (02359), BeiGene (06160), Lao Poo Gold (06181), Horizon Robotics (09660), and CanSino Biologics (09926) [1] - The contract sizes for the new options are as follows: Zijin Gold International (200 shares), WuXi AppTec (500 shares), BeiGene (200 shares), Lao Poo Gold (100 shares), Horizon Robotics (3,000 shares), and CanSino Biologics (1,000 shares) [2] Group 2: Market Performance - The average daily trading volume of HKEX's derivatives market reached 1,662,751 contracts last year, marking a 7% year-on-year increase and setting a new record [1] - Stock options, including monthly and weekly expiry contracts, were among the most actively traded products, with an average daily trading volume of 879,831 contracts, a 22% year-on-year increase and a new record high [1]